Loading organizations...
Israel Biotech Fund is a venture capital firm based in Rehovot, Israel, that invests in clinical-stage Israeli biotechnology and pharmaceutical companies, focusing on advancing novel therapeutic assets in areas like oncology and immuno-oncology. The firm provides capital and strategic support to bridge groundbreaking research with commercialization in Israel's life sciences sector. It has raised two dedicated funds, with its initial fund totaling $100 million and a second fund closing at $112 million, backed by limited partners including Biogen and Harel Insurance. Its portfolio features companies such as Ayala Pharmaceuticals, Biond Biologics, and Biosight, while its advisory board has included industry veterans like Sol Barer, founder of Celgene, and former Pfizer CEO Jeff Kindler. The firm was founded in 2014 by David Sidransky and Yuval Cabilly.
Key people at Israel Biotech Fund.
Israel Biotech Fund was founded in 2014 by David Sidransky (Co-Founder and General Partner) and Yuval Cabilly (Co-Founder and General Partner).
Key people at Israel Biotech Fund.
Israel Biotech Fund has 2 tracked investments across 2 companies. The latest tracked deal is $45.0M Series C in Ukko in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 8, 2026 | Ukko | $45.0M Series C | Israel Biotech Fund | Kira Peikoff, Fall Line Capital, Khosla Ventures, Sanara Capital |
| May 28, 2019 | Ayala Pharmaceuticals | $30.0M Series B | Novartis | Harel Insurance Investments & Financial Services, SBI JI Innovation Fund |
Israel Biotech Fund was founded in 2014 by David Sidransky (Co-Founder and General Partner) and Yuval Cabilly (Co-Founder and General Partner).
